HPV vaccines with broadest ever therapeutic range to enter clinical trial |
Clinical News
eMediNexus Coverage from: 
HPV vaccines with broadest ever therapeutic range to enter clinical trial

1 Read Comments                

An HPV vaccine which may act against persistent HPV infections and reduce the risk of women developing cervical cancer is going to be tested in clinical trial. Human papilloma virus infections occur commonly, but about 10% of infections are not cleared, with persistent infection of some types of HPV known to increase the risk of number of cancers, including cervical cancer. The new trial, expected to begin in March, is an international endeavor planned to involve 15 hospitals from UK and Belgium.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now